Business Context and Reporting Period
This Form 8-K Current Report was filed by Acadia Healthcare Company, Inc. on May 23, 2024. The filing primarily addresses significant corporate governance changes, executive leadership transitions, and the results of the Company's annual meeting of stockholders held on the same date.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on corporate events and executive compensation arrangements.
Material Changes and Executive Actions
Executive Leadership Transition
- Appointment of Chief Operating Officer: Dr. Nasser Khan was appointed as Chief Operating Officer, effective June 30, 2024. He previously served as Operations Group President for the Company's comprehensive treatment center business line since September 2022.
- Retirement of Executive Vice President: John S. Hollinsworth will retire as Executive Vice President of Operations effective June 30, 2024.
Compensation and Severance Arrangements
- Dr. Nasser Khan:
- Base Salary: $515,000 annually.
- Target Annual Cash Bonus: 85% of Base Salary.
- Severance upon Qualifying Termination: Includes 12 months of Base Salary, full vesting of time-based equity awards, and prorated performance bonuses.
- John S. Hollinsworth:
- Consulting Arrangement: Will provide transition advisory services through December 31, 2024, for a monthly payment of $10,000.
- Prorated 2024 annual cash bonus eligibility based on performance achievement.
Corporate Governance Changes
- Board Declassification: Stockholders approved an amendment to the Certificate of Incorporation to declassify the Board of Directors. This amendment became effective upon filing with the Delaware Secretary of State on May 23, 2024.
- Director Elections: Three Class I directors were elected to serve until the 2027 annual meeting:
- E. Perot Bissell (70.8M For, 15.6M Against)
- Vicky B. Gregg (83.7M For, 2.7M Against)
- Christopher H. Hunter (85.1M For, 1.3M Against)
Outlook, Risks, and Contingencies
The filing does not provide specific forward-looking guidance, risk factors, or contingencies beyond the standard disclosures regarding the execution of employment and separation agreements. The primary operational impact noted is the leadership transition effective June 30, 2024.
Investor Verification Checklist
- Verify the effective date of Dr. Khan's new role and Mr. Hollinsworth's retirement (June 30, 2024).
- Review the full text of the Employment Agreement (Exhibit 10.1) and Separation Agreement (Exhibit 10.2) for detailed performance metrics and termination conditions.
- Confirm the implications of the Board declassification on future director election cycles.
- Note the significant "Against" votes for director E. Perot Bissell (approx. 18% of votes cast) compared to other nominees.